Stock AnalizJazz Pharmaceuticals (JAZZ) earnings for the quarter ended September 2026: EPS misses estimates
Jazz Pharmaceuticals reported results for the quarter ended September 2026 on November 2, 2026. Adjusted earnings per share came in at -$3.88 against the analysts’ average forecast of -$2.38, a miss of 63.4%.
Revenue for the quarter was $1.24 billion, up 10.4% from $1.13 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 6.4% on the first trading day after the report.
The last four quarters
Jazz Pharmaceuticals has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$3.88 | -$2.38 | −63.4% | +10% | +6.4% |
| Jun 2026 | $5.71 | $6.18 | −7.5% | +16% | +3.5% |
| Mar 2026 | $6.34 | $4.66 | +36.2% | +19% | +9.9% |
| Dec 2025 | $6.64 | $6.51 | +2.0% | +10% | +13.6% |
What comes next
Analysts expect EPS of $6.64 for the next quarter on average and $14.94 for the fiscal year ending December 31, 2026.
The average analyst price target is $296.77, 23% above the current price of $241.55.
Valuation and score
Jazz Pharmaceuticals scores 1.0 out of 5 overall on Stock Analiz (weak), trades at a trailing P/E of about 78.7, and its intrinsic value under moderate assumptions is about 44% below the current market value. Full Jazz Pharmaceuticals analysis with 10 years of financials
Frequently asked questions
What was Jazz Pharmaceuticals’s EPS for the quarter ended September 2026?
-$3.88 adjusted per share, against an analyst consensus of -$2.38.
How much revenue did Jazz Pharmaceuticals report?
$1.24 billion, up 10.4% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.